Results 161 to 170 of about 510,697 (405)

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure [PDF]

, 2022
Atul Deodhar, Bernard Combe, Ana P. Accioly, Rebecca Bolce, Danting Zhu, Amanda M. Gellett, Aubrey Trevelin Sprabery, Gerd R Burmester   +7 more
openalex   +1 more source

Alterations in brain metabolites in rats with experimental periodontitis: A metabolomic approach

Journal of Periodontology, EarlyView.
Abstract Background Periodontitis (PD) is a chronic inflammatory disease with systemic effects. Emerging evidence suggests a link between periodontal inflammation and neurological changes, but the biochemical mechanisms in key brain regions, such as the hippocampus and amygdala, remain unclear.
Ramona Ramalho de Souza Pereira, Caíque Olegário Diniz e Magalhães, Elizabeth Luciana Marinho Miguel, Larissa Vieira Toledo, Débora Ribeiro Orlando, Alan Rodrigues Teixeira Machado, Bruno Del Bianco Borges, Luciano José Pereira, Marco Fabrício Dias‐Peixoto, Eric Francelino Andrade   +9 more
wiley   +1 more source

The role of the host—Neutrophil biology

Periodontology 2000, EarlyView., 2023
Abstract Neutrophilic polymorphonuclear leukocytes (neutrophils) are myeloid cells packed with lysosomal granules (hence also called granulocytes) that contain a formidable antimicrobial arsenal. They are terminally differentiated cells that play a critical role in acute and chronic inflammation, as well as in the resolution of inflammation and wound ...
Iain L. C. Chapple, Josefine Hirschfeld, Alpdogan Kantarci, Asaf Wilensky, Lior Shapira   +4 more
wiley   +1 more source

AB1311 Ultrasound evaluation of enthesis in psoriatic arthritis: a systematic literature review [PDF]

, 2018
I. Janta, Tania Gudu, Ruxandra Ionescu
openalex   +1 more source

Peripheral γδ T Cells Regulate Neutrophil Expansion and Recruitment in Experimental Psoriatic Arthritis

Arthritis & Rheumatology, 2022
C. Nguyen, H. Furuya, D. Das, A. Marusina, A. Merleev, R. Ravindran, Z. Jalali, I. Khan, E. Maverakis, I. Adamopoulos   +9 more
semanticscholar   +1 more source

Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All

Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]

, 2019
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M, Liao, Wilson, Ly, Karen, Orbai, Ana-Maria, Smith, Mary P   +4 more
core  

The Impact of Methotrexate on Cardiovascular Outcomes in Psoriasis: A Systematic Review and Meta‐Analysis

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic immune‐mediated inflammatory disease with a global prevalence of 2%–3% and 1.3% in Brazil. It is associated with comorbidities such as obesity, hypertension, and diabetes, all of which contribute to increased cardiovascular risk due to systemic inflammation and endothelial dysfunction.
Tiago A. S. Costa, Sheila T. K. Medorima, Renata F. Magalhães   +2 more
wiley   +1 more source

Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son, Yves Julien Mbama Biloa, Pauline Gouttefarde, Thomas Franck, Gilles Cizeron, Mathieu Oriol, François Maccari, Elisa Cinotti, Beatrice Trombert‐Paviot, Bienvenu Bongue, Jean‐Luc Perrot   +10 more
wiley   +1 more source